Naveris, Inc., a leader in precision oncology diagnostics for viral-induced cancers, announced new data presentation at the 2024 Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), held from September 28 to October 1, 2024, in Miami Beach, Florida. The presentations showcase the ongoing innovation of the NavDx® test, the first clinically validated circulating Tumor Tissue Modified Viral (TTMV®)-HPV DNA blood test designed to assist in the detection and management of HPV-driven oropharyngeal cancers.
“The AAO-HNS meeting provides a crucial platform for sharing our latest advancements in detecting and managing HPV-associated oropharyngeal cancer,” stated Barry M. Berger, M.D., Chief Medical Officer at Naveris. “The NavDx test continues to demonstrate its value in detecting molecular residual disease, enabling clinicians to monitor patients post-treatment with precision and make informed decisions that directly impact patient care.”
Oral Presentations:
Naveris will present three oral sessions during the Scientific Oral Presentations 1 – Head and Neck Surgery on Saturday, September 28, 2024, from 9:30 AM to 10:30 AM EDT at the Miami Beach Convention Center (MBCC), Room 208.
- 9:42 AM – 9:48 AM EDT
Title: Circulating Tumor Tissue-Modified-Viral-HPV DNA and Correlation With Disease Burden in Oropharyngeal Cancer
Presenting Author: Jaclyn Lee, M.D.
Senior Author: Michael C. Topf, M.D., MSCI
Vanderbilt University Medical Center, Nashville, TN
This study evaluates the association between pre-treatment TTMV-HPV DNA and clinical tumor and nodal staging in HPV+ oropharyngeal squamous cell carcinoma (OPSCC), reporting an independent correlation with clinical nodal staging. - 9:54 AM – 10:00 AM EDT
Title: Association of Circulating Tumor HPV DNA Score and Clinicopathologic Characteristics in HPV-Associated Oropharyngeal Cancer
Presenting Author: Shimrit Sharav, M.D.
Senior Author: Terry Day, M.D.
Sarah Cannon Cancer Institute, Charleston, SC
This study explores the correlation between TTMV-HPV DNA and clinicopathological factors, highlighting significant associations with nodal disease burden in HPV+ OPSCC patients. - 10:12 AM – 10:18 AM EDT
Title: Liquid Biopsy in Diagnosis and Surveillance of HPV-Associated Oropharyngeal Cancer: A Systematic Review
Presenting Author: Susmita Chennareddy, B.A.
Senior Author: Scott A. Roof, M.D.
Icahn School of Medicine at Mount Sinai, New York, NY
This review assesses the diagnostic accuracy of circulating tumor DNA (ctDNA) technologies in HPV-associated OPSCC, concluding that ctDNA shows high sensitivity and specificity for disease detection, treatment monitoring, and recurrence surveillance.
Additional Presentations:
On Sunday, September 29, 2024, from 9:30 AM to 10:30 AM EDT in MBCC, Room 208, Naveris will present:
9:54 AM – 10:00 AM EDT
Title: Examining Patients’ Opinions on NavDx During Head and Neck Cancer Surveillance: An Exploratory Study
Presenting Author: Amanda Joy Bastien, M.D.
Senior Author: Allen S. Ho, M.D.
Cedars Sinai, Los Angeles, CA
This study evaluates patient feedback on NavDx as a molecular surveillance tool, emphasizing convenience, cost, and perceived test validity.
Panel Discussions:
Monday, September 30, 2024 | 8:00 AM – 9:00 AM EDT | MBCC, Room 207
Title: HPV: Is It in Your DNA
Moderator: Marianne Abouyared, M.D.
Panelists include experts from multiple esteemed institutions.
This panel will discuss the role of HPV in oropharyngeal cancers and the integration of circulating HPV DNA (HPV ctDNA) as a surveillance tool in clinical practice.
Poster Presentations:
Monday, September 30, 2024 | 12:00 PM – 1:00 PM EDT | Exhibit Hall A-D
Title: Association Between Routine Laboratory Inflammatory Indicators and Circulating Tumor DNA Levels in HPV-Positive Oropharyngeal Carcinoma
Presenting Author: Ryan S. Ziltzer, M.D., MPH
Senior Author: Meghan T. Turner, M.D.
West Virginia University, Morgantown, WV
This pilot study suggests that certain inflammatory indices correlate with higher TTMV-HPV DNA scores in OPSCC, indicating their potential as surrogate markers for disease monitoring.
Naveris will exhibit at Booth #718, where attendees can learn more about NavDx and its role in optimizing surveillance of oropharyngeal cancer recurrence.
For more information about Naveris and NavDx, visit Naveris and NavDx.
About Naveris
Naveris is a privately held precision oncology diagnostics company dedicated to improving outcomes for individuals at risk of viral-induced cancers through novel molecular diagnostics. Founded in 2017, Naveris operates accredited high-complexity testing clinical laboratories in Massachusetts and North Carolina. For more information, please visit Naveris and NavDx. NavDx is not cleared or approved by the US Food and Drug Administration (FDA).
